Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Autor: Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A.

Publikováno v: LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BASE-Bielefeld Academic Search Engine
Lancet Oncology, 20(6), 781-794. Lancet Publishing Group
Richardson, P G, Oriol, A, Beksac, M, Liberati, A M, Galli, M, Schjesvold, F, Lindsay, J, Weisel, K, White, D, Facon, T, San Miguel, J, Sunami, K, O'Gorman, P, Sonneveld, P, Robak, P, Semochkin, S, Schey, S, Yu, X, Doerr, T, Bensmaine, A, Biyukov, T, Peluso, T, Zaki, M, Anderson, K, Dimopoulos, M, OPTIMISMM trial investigators & Abildgaard, N 2019, ' Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 6, pp. 781-794 . https://doi.org/10.1016/S1470-2045(19)30152-4

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has show

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cccf2220a5bc187bbb4a4254d3d0f52
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4189

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Autor: Went, M, Sud, A, Försti, A, Halvarsson, BM, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Jöckel, KH, Johnsson, E, Kristinsson, SY, Mellqvist, UH, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, ZS, Muir, K, Pashayan, N, Nickel, J, Nöthen, MM, Rafnar, T, Ross, FM, da Silva Filho, MI, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, AK, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, Houlston, RS, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Olama, AAA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, The PRACTICAL Consortium

© 2018, The Author(s). Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1131::f7734f9e27f34106bbe3f4a96df7e407
https://lirias.kuleuven.be/handle/123456789/633372

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study

Autor: Kumar S. K., Lee J. H., Lahuerta J. J., Morgan G., Richardson P. G., Crowley J., Haessler J., Feather J., Hoering A., Moreau P., LeLeu X., Hulin C., Klein S. K., Sonneveld P., Siegel D., Bladé J., Goldschmidt H., Jagannath S., Miguel J. S., Orlowski R., Palumbo A., Sezer O., Rajkumar S. V., Durie B. G. International Myeloma Working Group Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben Yehuda D, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Chanan Khan A, Chen WM, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen HE, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nahi H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Rajkumar SV, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, San Miguel J, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Vande Broek I, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J., CAVO, MICHELE

Publikováno v: Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, Leleu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, Abildgaard, N, Abonour, R, Alexanian, R, Alsina, M, Anderson, K C, Attal, M, Avet-Loiseau, H, Badros, A, Baris, D, Barlogie, B, Bataille, R, Beksaç, M, Belch, A, Ben-Yehuda, D, Bensinger, B, Leif Bergsagel, P, Bird, J, Bladé, J, Boccadoro, M, Cavo, M, Chanan-Khan, A, Ming Chen, W, Child, T, Chim, J, Chng, W-J, Johnsen, H & on behalf of the International Myeloma Working Group 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : A multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Kumar, S K, Lee, JH, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, International Myeloma Working Group & Abildgaard, N 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : a multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Leukemia, 26(1), 149-157. Nature Publishing Group

Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current er

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2dbe6ffe8c2635e6295f17f425b101c
https://pure.au.dk/portal/da/publications/risk-of-progression-and-survival-in-multiple-myeloma-relapsing-after-therapy-with-imids-and-bortezomib(9b065552-2900-4784-9cd2-fd53f87d51ac).html

European Myeloma Network. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Autor: Dimopoulos, Ma, Palumbo, Antonio, Attal, M, Beksaç, M, Davies, Fe, Delforge, M, Einsele, H, Hajek, R, Harousseau, Jl, da Costa FL, Ludwig, H, Mellqvist, Uh, Morgan, Gj, San Miguel JF, Zweegman, S, Sonneveld, P.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______970::3072efb83cca8f71eee120f5b1b3fbfc
http://hdl.handle.net/2318/99347

Impaired Stem Cell Mobilization by Fludarabinde in MM: Results from a Randomized Phase II Trial

Autor: Johnsen, HE, Lennhoff, S, Tangen, Gluud, C, Meldgaard Knudsen, Lene, Mylin, AK, Gimsing, P, Gregersen, H, Abildgaard, Niels, Nielsen, JL, Andersen, NF, Plesner, Torben, Vangsted, AJ, Mourits-Andersen, T, Mellqvist, UH

Publikováno v: Johnsen, HE, Lennhoff, S, Tangen,, Gluud, C, Meldgaard Knudsen, L, Mylin, AK, Gimsing, P, Gregersen, H, Abildgaard, N, Nielsen, JL, Andersen, NF, Plesner, T, Vangsted, AJ, Mourits-Andersen, T & Mellqvist, UH 2009, ' Impaired Stem Cell Mobilization by Fludarabinde in MM: Results from a Randomized Phase II Trial ', XII th International Myeloma Workshop, Washington DC, United States, 26/02/2009-01/03/2009 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::63106d421a94c4c7073aea7948731394
https://portal.findresearcher.sdu.dk/da/publications/78a96630-2443-11de-ae62-000ea68e967b